Melding breast and prostate cancers alter egos

References

• Jensen EV. On the mechanism of estrogen action. Perspect. Biol. Med.6, 47–59 (1962).
   PubMedGoogle Scholar
• Toft D, Gorski J. A receptor molecule for estrogens: isolation from the rat uterus and preliminary characterization. Proc. Natl Acad. Sci. USA55, 1574–1581 (1966).
   PubMed Web of Science ®Google Scholar
• Dahlberg E, Snochowski M, Gustafsson JA. Regulation of the androgen and glucocorticoid receptors in rat and mouse skeletal muscle cytosol. Endocrinology108, 1431–1440 (1981).
   PubMed Web of Science ®Google Scholar
• Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet2, 104–107 (1896).
   Google Scholar
• Boyd S. On oophorectomy in cancer of the breast. BMJ2, 1161–1167 (1900).
   Google Scholar
• Huggins C, Stevens RE, Hodges CV. Studies on prostatic cancer. II. The effect of castration on advanced carcinoma of the prostate gland. Arch. Surg.43, 209–212 (1941).
   Google Scholar
• Ricketts D, Turnbull L, Ryall G et al. Estrogen and progesterone receptors in the normal female breast. Cancer Res.51, 1817–1822 (1991).
   PubMed Web of Science ®Google Scholar
• Lamb DJ, Weigel VL, Marcelli M. Androgen receptors and their biology. Vitam. Horm.62, 199–230 (2001).
   PubMedGoogle Scholar
• Anderson E, Clarke RB, Howell A. Estrogen responsiveness and control of normal human breast proliferation. J. Mammary Gland Biol. Neoplasia3, 23–35 (1998).
   PubMed Web of Science ®Google Scholar
• Henderson BE, Feigelson HS. Hormonal carcinogenesis. Carcinogenesis21, 427–433 (2000).
   PubMed Web of Science ®Google Scholar
• Mangelsdorf DJ, Thummel C, Beato M et al. The nuclear receptor superfamily: the second decade. Cell83, 835–839 (1995).
   PubMed Web of Science ®Google Scholar
• Lubahn DB, Joseph DR, Sullivan PM, Willard HF, French FS, Wilson EM. Cloning of human androgen receptor complementary DNA and localization to the X chromosome. Science240, 327–330 (1988).
   PubMed Web of Science ®Google Scholar
• Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA. Cloning of a novel receptor expressed in rat prostate and ovary. Proc. Natl Acad. Sci. USA93, 5925–5930 (1996).
   PubMed Web of Science ®Google Scholar
• Mosselman S, Polman J, Dijkema R. ERβ: identification and characterization of a novel human estrogen receptor. FEBS Lett.392, 49–53 (1996).
   PubMed Web of Science ®Google Scholar
• McInerney EM, Tsai MJ, O’Malley BW, Katzenellenbogen BS. Analysis of estrogen receptor transcriptional enhancement by a nuclear hormone receptor coactivator. Proc. Natl Acad. Sci. USA93, 10069–10073 (1996).
   PubMed Web of Science ®Google Scholar
• Yeh S, Chang C. Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells. Proc. Natl Acad. Sci. USA93, 5517–5521 (1996).
   PubMed Web of Science ®Google Scholar
• Lannigan DA. Estrogen receptor phosphorylation. Steroids68, 1–9 (2003).
   PubMed Web of Science ®Google Scholar
• Belandia B, Orford RL, Hurst HC, Parker MG. Targeting of SWI/SNF chromatin remodeling complexes to estrogen-responsive genes. EMBO J.21, 4094–4103 (2002).
   PubMed Web of Science ®Google Scholar
• Kang YK, Guermah M, Yuan CX, Roeder RG. The TRAP/mediator coactivator complex interacts directly with estrogen receptors α and β through the TRAP220 subunit and directly enhances estrogen receptor function in vitro. Proc. Natl Acad. Sci. USA99, 2642–2647 (2002).
   PubMed Web of Science ®Google Scholar
• Rachez C, Gamble M, Chang CP, Atkins GB, Lazar MA, Freedman LP. The DRIP complex and SRC-1/p160 coactivators share similar nuclear receptor binding determinants but constitute functionally distinct complexes. Mol. Cell Biol.20, 2718–2726 (2000).
   PubMed Web of Science ®Google Scholar
• Chen D, Huang S-M, Stallcup MR. Synergistic, p160 coactivator-dependent enhancement of estrogen receptor function by CARM1 and p300. J. Biol. Chem.275, 40810–40816 (2000).
   PubMedGoogle Scholar
• Lopez-Garcia J, Periyasamy M, Thomas RS et al. ZNF366 is an estrogen receptor corepressor that acts through CtBP and histone deacetylases. Nucl. Acids Res.34, 6126–6136 (2006).
   PubMedGoogle Scholar
• Jeong B-C, Hong CY, Chattopadhyay S et al. Androgen receptor corepressor-19 kDa (ARR19), a leucine-rich protein that represses the transcriptional activity of androgen receptor through recruitment of histone deacetylase. Mol. Endocrinol.18, 13–25 (2004).
   PubMedGoogle Scholar
• McKenna NJ, O’Malley BW. Combinatorial control of gene expression by nuclear receptors and coregulators. Cell108, 465–474 (2002).
   PubMed Web of Science ®Google Scholar
• Webb P, Nguyen P, Kushner PH. Differential SERM effects on corepressor binding dictate ERα activity in vivo. J. Biol. Chem.278, 6912–6920 (2003).
   PubMedGoogle Scholar
• Frasor J, Danes JM, Komm B, Chang KCN, Lyttle CR, Katzenellenbogen BS. Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology144, 4562–4574 (2003).
   PubMed Web of Science ®Google Scholar
• Eliassen AH, Missmer SA, Tworoger SS, Hankinson SE. Endogenous steroid hormone concentrations and risk of breast cancer: does the association vary by a woman’s predicted breast cancer risk? J. Clin. Oncol.24, 1823–1830 (2006).
   PubMed Web of Science ®Google Scholar
• Missmer SA, Eliassen AH, Barbieri RL et al. Endogenous estrogen, androgen, progesterone concentrations and breast cancer risk among postmenopausal women. J. Natl Cancer Inst.96, 1856–1865 (2004).
   PubMed Web of Science ®Google Scholar
• Cummings SR, Lee JS, Lui LY, Stone K, Ljung BM, Cauleys JA. Sex hormones, risk factors, and risk of estrogen receptor-positive breast cancer in older women: a long-term prospective study. Cancer Epidemiol. Biomarkers Prev.14, 1047–1051 (2005).
   PubMedGoogle Scholar
• Beattie MS, Costantino JP, Cummings SR et al. Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1). J. Natl Cancer Inst.98, 110–115 (2006).
   PubMedGoogle Scholar
• Parsons JK, Carter HB, Platz EA, Wright EJ, Landis P, Metter EJ. Serum testosterone and the risk of prostate cancer: potential implications for testosterone therapy. Cancer Epidemiol. Biomarkers Prev.14, 2257–2260 (2005).
   PubMed Web of Science ®Google Scholar
• Chen C, Weiss NS, Stanczyk FZ et al. Endogenous sex hormones and prostate cancer risk: a case-control study nested within the Carotene and Retinol Efficacy Trial. Cancer Epidemiol. Biomarkers Prev.12, 1410–1416 (2003).
   PubMed Web of Science ®Google Scholar
• Statin P, Lumme S, Tenkanen L et al. High levels of circulating testosterone are not associated with increased prostate cancer risk: a pooled prospective study. Int. J. Cancer108, 418–424 (2004).
   PubMedGoogle Scholar
• Zhang PL, Rosen S, Veeramachaneni R, Kao J, DeWolf WC, Bubley G. Association between prostate cancer and serum testosterone levels. Prostate53, 179–182 (2002).
   PubMed Web of Science ®Google Scholar
• Schatzl G, Madersbacher S, Thurridl T et al. High-grade prostate cancer is associated with low serum testosterone levels. Prostate47, 52–58 (2001).
   PubMed Web of Science ®Google Scholar
• Imamoto T, Suzuki H, Fukasawa S et al. Pretreatment serum testosterone level as a predictive factor of pathological stage in localized prostate cancer patients treated with radical prostatectomy. Eur. Urol.47, 308–312 (2005).
   PubMed Web of Science ®Google Scholar
• Platz EA, Leitzmann MF, Rifai N et al. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Cancer Epidemiol. Biomarkers Prev.14, 1262–1269 (2005).
   PubMed Web of Science ®Google Scholar
• Imamoto T, Suzuki H, Akakura K et al. Pretreatment serum level of testosterone as a prognostic factor in Japanese men with hormonally treated stage D2 prostate cancer. Endocr. J.48, 573–578 (2001).
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Groupt (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet365, 1687–1717 (2005).
   PubMed Web of Science ®Google Scholar
• Fisher B, Costantino JP, Wickerham DL et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J. Natl Cancer Inst.90, 1371–1388 (1998).
   PubMed Web of Science ®Google Scholar
• Forbes JF, Cuzick J, Buzdar A et al.; Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists’ Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol.9, 45–53 (2008).
   PubMed Web of Science ®Google Scholar
• Thompson IM, Goodman PJ, Tangen CM et al. The influence of finasteride on the development of prostate cancer. N. Engl. J. Med.349, 215–224 (2003).
   PubMed Web of Science ®Google Scholar
• Schatzl G, Madersbacher S, Gsur A et al. Association of polymorphisms within androgen receptor, 5α-reductase, and PSA genes with prostate volume, clinical parameters, and endocrine status in elderly men. Prostate52, 130–138 (2002).
   PubMedGoogle Scholar
• Li CI, Malone KE, Weiss NS, Daling JR. Tamoxifen therapy for primary breast cancer and risk of contralateral breast cancer. J. Natl Cancer Inst.93, 1008–1013 (2001).
   PubMedGoogle Scholar
• Kuukasjarvi T, Kononen J, Helin H, Holli K, Isola J. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J. Clin. Oncol.14, 2584–2589 (1996).
   PubMed Web of Science ®Google Scholar
• Taplin ME, Bubley GJ, Ko YJ et al. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res.59, 2511–2515 (1999).
   PubMed Web of Science ®Google Scholar
• Lewis JS, Jordan VC. Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance. Mutat. Res.591, 247–263 (2005).
   PubMed Web of Science ®Google Scholar
• Smith CL. Cross-talk between peptide growth factor and estrogen receptor signaling pathways. Biol. Reprod.58, 627–632 (1998).
   PubMed Web of Science ®Google Scholar
• Russell PJ, Bennett S, Stricker P. Growth factor involvement in progression of prostate cancer. Clin. Chem.44, 705–723 (1998).
   PubMed Web of Science ®Google Scholar
• Culig Z, Hobisch A, Cronauer MV et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res.54, 5474–5478 (1994).
   PubMed Web of Science ®Google Scholar
• Benz CC, Scott GK, Sarup JC et al. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res. Treat.24, 85–95 (1993).
   Web of Science ®Google Scholar
• Sørlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. PNAS98, 10869–10874 (2001).
   PubMed Web of Science ®Google Scholar
• Isaacs JT. The biology of hormone refractory prostate cancer. Why does it develop? Urol. Clin. North. Am.26, 263–273 (1999).
   PubMed Web of Science ®Google Scholar
• Yao K, Lee ES, Bentrem DJ et al. Antitumor action of physioloigical estradiol on tamoxifen-stimulated breast tumors grown in athymic mice. Clin. Cancer Res.6, 2028–2036 (2000).
   PubMed Web of Science ®Google Scholar
• Liu J, Geller J, Albert J, Kirshner M. Acute effects of testicular and adrenal cortical blockade on protein synthesis and dihydrotestosterone content of human prostate tissue. J. Clin. Endocrinol. Metab.61, 129–133 (1985).
   PubMedGoogle Scholar
• Mostaghel EA, Page St, Lin DW et al. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res.67, 5033–5041 (2007).
   PubMed Web of Science ®Google Scholar
• The International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome. Nature409, 860–921 (2001).
   PubMed Web of Science ®Google Scholar
• Le Early L, Donlon T, Kolonel LN, Henderson BE, Wilkens LR. Estrogen metabolism – related genes and breast cancer risk: the multiethnic cohort study. Cancer Epidemiol. Biomarkers Prev.14, 1998–2003 (2005).
   PubMedGoogle Scholar
• Sangrajrang S, Sato Y, Sakamoto H et al. Genetic polymorphisms of estrogen metabolizing enzyme and breast cancer risk in Thai women. Int. J. Cancer125, 837–843 (2009).
   PubMed Web of Science ®Google Scholar
• Silva SN, Cabral MN, Bezerra de Castro G et al. Breast cancer risk and polymorphisms in genes involved in metabolism of estrogens (CYP17, HSD17β1, COMT and MnSOD): possible protective role of MnSOD gene polymorphism Val/Ala and Ala/Ala in women that never breast fed. Oncol. Rep.16, 781–788 (2006).
   PubMedGoogle Scholar
• Agarwal VR, Bulun SE, Leitch M, Rohrich R, Simpson ER. Use of alternative promoters to express the aromatase cytochrome P450 (CYP19) gene in breast adipose tissues of cancer-free and breast cancer patients. J. Clin. Endocrinol. Metab.81, 3843–3849 (1996).
   PubMed Web of Science ®Google Scholar
• Tekmal RR, Ramachandra N, Gubba S et al. Overexpression of int-5/aromatase in mammary glands of transgenic mice results in the induction of hyperplasia and nuclear abnormalities. Cancer Res.56, 3180–3185 (1996).
   PubMed Web of Science ®Google Scholar
• Haiman CA, Hankinson SE, Spiegelman D et al. A tetracucleotide repeat polymorphism in CYP19 and breast cancer risk. Int. J. Cancer87, 204–210 (2000).
   PubMed Web of Science ®Google Scholar
• Probst-Hensch NM, Ingles SA, Diep AT et al. Aromatase and breast cancer susceptibility. Endocr. Relat. Cancer6, 165–173 (1999).
   PubMed Web of Science ®Google Scholar
• Kristensen VN, Andersen TI, Lindblom A, Erikstein B, Magnus P, Borresen-Dale AL. A rare CYP19 (aromatase) variant may increase the risk of breast cancer. Pharmacogenetics8, 43–48 (1998).
   PubMedGoogle Scholar
• Huang CS, Chern HD, Chang KJ, Cheng CW, Hsu SM, Shen CT. Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP17, CYP1A1, and COMT. A multigenic study on cancer susceptibility. Cancer Res.5, 4870–4875 (1999).
   Google Scholar
• Thompson PA, Shields PG, Freudenheim JL et al. Genetic polymorphisms in catechol-O-methyltransferase, menopausal status, and breast cancer risk. Cancer Res.58, 2107–2110 (1998).
   PubMed Web of Science ®Google Scholar
• Wang Q, Li W, Zhang Y et al. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell138, 245–256 (2009).
   PubMed Web of Science ®Google Scholar
• Choong CS, Wilson EM. Trinucleotide repeats in the human androgen receptor: a molecular basis for disease. J. Mol. Endocrinol.21, 235–257 (1998).
   PubMed Web of Science ®Google Scholar
• Wang W, John EM, Ingles SA. Androgen receptor and prostate-specific antigen gene polymorphisms and breast cancer in African–American women. Cancer Epidemiol. Biomarkers Prev.14, 2990–2994 (2005).
   PubMed Web of Science ®Google Scholar
• Coetzee GA, Ross RK. Prostate cancer and the androgen receptor. J. Natl Cancer Inst.86, 872–873 (1994).
   PubMed Web of Science ®Google Scholar
• Bratt O, Borg A, Kristofferson U, Lundgren R, Zhang QX, Olsson H. CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not prostate cancer risk. Br. J. Cancer81, 672–676 (1999).
   PubMed Web of Science ®Google Scholar
• Giovannucci E, Stampfer MJ, Krithivas K et al. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc. Natl Acad. Sci. USA94, 3320–3323 (1997).
   PubMed Web of Science ®Google Scholar
• Hsing AW, Gao YT, Wu G et al. Polymorphic CAG and GGN repeat lengths in the androgen receptor gene and prostate cancer risk: a population-based case-control study in China. Cancer Res.60, 5111–5116 (2000).
   PubMed Web of Science ®Google Scholar